News

Cumbersome security procedures, rising airfares, and shrinking legroom have made commercial air travel difficult enough these days — even for healthy passengers. Imagine how much harder it is for patients with rare diseases who must get to doctors’ appointments or clinical trials that are hundreds of miles away from home.

Rituximab, an immunosuppressant antibody, alleviates skin fibrosis in patients with systemic sclerosis (SSc) and was also found to be generally safe, according to a study. The study, “Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study,” was published in the…

Epigenetic changes — chemical modifications in DNA that affect gene expression (the process by which information within a gene gives rise to a functional product) — may be involved in the development of systemic scleroderma, a study says. The findings of the study, “Integrative analysis of DNA methylation…

Men older than 50 with diffuse cutaneous systemic sclerosis (dcSSc) have higher levels of estradiol, an active form of estrogen, in their blood compared to healthy males, a study suggests. High estradiol levels correlated with worse survival and cardiac complications. The results suggest that estradiol is a potential therapeutic…

TLY012, a lab-made equivalent of a natural protein called TRAIL, can reverse skin fibrosis in mice with scleroderma by blocking important cells involved in the underlying mechanism of skin scarring, a research study found. Targeting TRAIL pathway and this novel engineered molecule may represent a promising anti-fibrotic strategy to arrest scleroderma in…